Scientists investigate how muscles bounce back after inactivity

NCT ID NCT04416191

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand how muscle health recovers after a period of disuse, like being in a cast. Researchers will immobilize one leg of healthy volunteers for two weeks, then measure muscle size and strength before and after. The study includes both younger (18-35) and older (60-85) adults to see how age affects recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18-35 and 60-85 yrs 2. Ability to sign informed consent 3. Free-living, prior to admission Exclusion Criteria: * History of cardiovascular disease (e.g., CHF, CAD, right-to-left shunt) * History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes * History of kidney disease or failure * Vascular disease * Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III * Use of anticoagulant therapy (e.g., Coumadin, heparin) * Elevated systolic pressure \>150 or a diastolic blood pressure \> 100 * Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators) * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Currently on a weight-loss diet * Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted) * Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted) * History of stroke with motor disability * A recent history (\<12 months) of GI bleed * History of liver disease * History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) * Pregnancy as determined by a pregnancy test * Any staff members who report directly to an investigator or who report to someone who reports directly to an investigator. * Any other condition or event considered exclusionary by the PI and faculty physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle disuse are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.